Cystic Fibrosis – Epidemiology – Europe
Clarivate Epidemiology's coverage of Cystic Fibrosis (CF) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of CF for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and Europe and 10 years for the other countries covered in this report.
Clarivate Epidemiology's CF forecast will answer the following questions:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of CF over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate’s Epidemiology provides at least 10 years of forecast data for the following CF patient populations:
- Incident cases of CF at birth.
- Diagnosed prevalent cases of CF
- Diagnosed prevalent cases stratified by CFTR mutation.
Note: Coverage may vary by country and region.
Table of contents
- Cystic Fibrosis - Epidemiology - Europe
- Epidemiology data
- Methods
- Literature review (studies included in/excluded from the analyses of cystic fibrosis)
- Birth incident cases
- Diagnosed prevalent cases of cystic fibrosis
- Diagnosed prevalent cases stratified by CFTR mutation
- Diagnosed drug-treated prevalent cases
- Risk / protective factors applied to disease forecast models
- Reference materials
- Bibliography
- Glossary
- Abbreviations table
Jagriti Prasad, M.P.H., is an associate epidemiologist at Clarivate. Prior to joining the company, she worked on a research project exploring trends in a rare cancer and its subtype using data spanning 44 years in the largest cancer registry of northern England (NRYPMDR). She obtained her M.P.H. from Newcastle University in the United Kingdom and her B.D.S. from Manipal University in India.
Jackie Liu, M.P.H., Ph.D., Manager, Epidemiology. She first joined Clarivate as a Medtech analyst and worked on forecasting the global vascular devices market. She received her Ph.D. in molecular genetics and her M.P.H. in epidemiology from the University of Toronto in Canada.